{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:59:23Z","timestamp":1794088763925,"version":"4.8.0"},"reference-count":108,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":109,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is growing clinical interest in strategies for improving clinical outcomes in patients with heart failure (HF) and obesity. The development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and of the dual glucose-dependent insulinotropic polypeptide (GIP)\/GLP-1 RA has expanded therapeutic options for this population. This expert consensus provides a comprehensive and pragmatic framework for the use of GLP-1 RAs and GIP\/GLP-1 RA in patients with HF, focusing on clinical integration, patient selection, safety, and tolerability. We review the evidence supporting their use in patients with HF with preserved ejection fraction (HFpEF), where clinical trials have demonstrated meaningful reductions in body weight alongside improvements in health status and exercise capacity. Whether these effects translate into fewer HF events or lower cardiovascular mortality remains uncertain, as current evidence is limited to two small trials with few observed events. In contrast, data regarding the efficacy and safety of these drugs in HF with reduced ejection fraction are scarce, with dedicated outcome trials yet to be launched. Finally, this document highlights knowledge gaps and outlines future research directions in this field.<\/jats:p>","DOI":"10.1002\/ejhf.70082","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T02:14:23Z","timestamp":1764296063000},"page":"2465-2479","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacological Treatment for Patients with Obesity and Heart Failure: Focus on Glucagon-Like Peptide-1 Receptor Agonists.\n                    <i>European Journal of Heart Failure<\/i>\n                    Expert Consensus Document"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2958-943X","authenticated-orcid":false,"given":"Luca","family":"Monzo","sequence":"first","affiliation":[{"name":"Centre d'Investigations Cliniques Plurith\u00e9matique 1433 and INSERM U1116 - DCAC, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset; Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Mullens","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Genk ,","place":["Belgium"]},{"name":"Hasselt University, Faculty of Medicine and Life Sciences , Diepenbeek ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Abdin","sequence":"additional","affiliation":[{"name":"Internal Medicine Clinic III, Cardiology, Angiology and Intensive Care Medicine, Saarland University Hospital , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u2018Prof. C.C. Iliescu\u2019 , Bucharest ,","place":["Romania"]},{"name":"University of Medicine Carol Davila , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seif","family":"El Hadidi","sequence":"additional","affiliation":[{"name":"Royal College of Surgeons in Ireland (RCSI) , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Gorter","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Centre Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo M.","family":"Inciardi","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiologic Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele G.","family":"Schiattarella","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9, Department of Cardiology, Angiology and Intensive Care Medicine, Max Rubner Center for Cardiovascular Metabolic Renal Research (MRC) , Berlin ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research), Partner Site Berlin , Berlin ,","place":["Germany"]},{"name":"Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbr\u00fcck Center for Molecular Medicine in the Helmholtz Association (MDC) , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Stolfo","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset; Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Cardiology, Cardiothoracic Department, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) , Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiologic Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"Centre d'Investigations Cliniques Plurith\u00e9matique 1433 and INSERM U1116 - DCAC, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2026021721495642700_ejhf70082-bib-0001","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026021721495642700_ejhf70082-bib-0002","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/ejhf.3676","article-title":"Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC","volume":"27","author":"Savarese","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0003","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ejhf.2894","article-title":"Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0004","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jacc.2005.08.050","article-title":"B-type natriuretic peptide levels in obese patients with advanced heart failure","volume":"47","author":"Horwich","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043384","article-title":"Hormonal gut-brain signaling for the treatment of obesity","volume":"24","author":"Roh","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026021721495642700_ejhf70082-bib-0006","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: From basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"2026021721495642700_ejhf70082-bib-0007","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","article-title":"GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice","volume":"58","author":"Noyan-Ashraf","year":"2009","journal-title":"Diabetes"},{"key":"2026021721495642700_ejhf70082-bib-0008","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"2026021721495642700_ejhf70082-bib-0009","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0010","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JOE-13-0414","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS","volume":"221","author":"Bloemendaal","year":"2014","journal-title":"J Endocrinol"},{"key":"2026021721495642700_ejhf70082-bib-0011","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021721495642700_ejhf70082-bib-0012","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021721495642700_ejhf70082-bib-0013","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021721495642700_ejhf70082-bib-0014","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40608-014-0024-2","article-title":"Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity","volume":"1","author":"Kistorp","year":"2014","journal-title":"BMC Obes"},{"key":"2026021721495642700_ejhf70082-bib-0015","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: A prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"key":"2026021721495642700_ejhf70082-bib-0016","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ejhf.2778","article-title":"Use of patient-reported outcomes in heart failure: From clinical trials to routine practice","volume":"25","author":"Savarese","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0017","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/ejhf.3440","article-title":"Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology","volume":"27","author":"Volterrani","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0018","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076838","article-title":"The different pathways of Epicardial adipose tissue across the heart failure phenotypes: From pathophysiology to therapeutic target","volume":"24","author":"Rossi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026021721495642700_ejhf70082-bib-0019","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0020","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: A secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"key":"2026021721495642700_ejhf70082-bib-0021","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"2026021721495642700_ejhf70082-bib-0022","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721495642700_ejhf70082-bib-0023","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0024","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021721495642700_ejhf70082-bib-0025","first-page":"491","article-title":"Relevance of body weight and weight change on cardiovascular benefit with semaglutide: a pre-specified analysis of the SELECT trial","volume":"17","author":"Deanfield","year":"2024","journal-title":"Obes Facts"},{"key":"2026021721495642700_ejhf70082-bib-0026","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1093\/eurheartj\/ehaf057","article-title":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: The PARAGON-HF trial","volume":"46","author":"Peikert","year":"2025","journal-title":"Eur Heart J"},{"key":"2026021721495642700_ejhf70082-bib-0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-024-00690-w","article-title":"Obesity, metabolic syndrome, and obesity paradox in heart failure: A critical evaluation","volume":"22","author":"Catalfamo","year":"2024","journal-title":"Curr Heart Fail Rep"},{"key":"2026021721495642700_ejhf70082-bib-0028","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/eurheartj\/ehad083","article-title":"Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: Revisiting the obesity paradox","volume":"44","author":"Butt","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021721495642700_ejhf70082-bib-0029","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019323","article-title":"Potential effects of bariatric surgery on the incidence of heart failure and atrial fibrillation in patients with type 2 diabetes mellitus and obesity and on mortality in patients with preexisting heart failure: A nationwide, matched, observational cohort study","volume":"10","author":"Hoskuldsdottir","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026021721495642700_ejhf70082-bib-0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","article-title":"Semaglutide and NYHA functional class in Obesity-related heart failure with preserved ejection fraction: The STEP-HFpEF program","volume":"84","author":"Schou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0031","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"2026021721495642700_ejhf70082-bib-0032","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cardfail.2025.01.022","article-title":"Efficacy of GLP-1 receptor agonists in patients with heart failure and mildly reduced or preserved ejection fraction: A systematic review and meta-analysis","volume":"31","author":"Waqas","year":"2025","journal-title":"J Card Fail"},{"key":"2026021721495642700_ejhf70082-bib-0033","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) \u2013 a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0034","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"2026021721495642700_ejhf70082-bib-0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dom.14862","article-title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial","volume":"25","author":"Neves","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026021721495642700_ejhf70082-bib-0036","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","article-title":"Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: A meta-analysis of the EXSCEL and FIGHT trials","volume":"29","author":"Neves","year":"2023","journal-title":"J Card Fail"},{"key":"2026021721495642700_ejhf70082-bib-0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.03.035","article-title":"GLP-1 receptor agonists in heart failure with reduced ejection fraction: Meta-analysis of randomized clinical trials","volume":"13","author":"Neves","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0038","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"2026021721495642700_ejhf70082-bib-0039","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021721495642700_ejhf70082-bib-0040","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721495642700_ejhf70082-bib-0041","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0042","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021721495642700_ejhf70082-bib-0043","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: A randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"key":"2026021721495642700_ejhf70082-bib-0044","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2019.12.063","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure","volume":"75","author":"Marso","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0045","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.119.041659","article-title":"Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: Insights from the EXSCEL trial","volume":"140","author":"Fudim","year":"2019","journal-title":"Circulation"},{"key":"2026021721495642700_ejhf70082-bib-0046","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"2026021721495642700_ejhf70082-bib-0047","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/dom.14997","article-title":"Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026021721495642700_ejhf70082-bib-0048","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00392-023-02362-6","article-title":"GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: An updated systematic review and meta-analysis","volume":"113","author":"Villaschi","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0049","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2020.09.007","article-title":"In-hospital outcomes after bariatric surgery in patients with heart failure","volume":"230","author":"Blumer","year":"2020","journal-title":"Am Heart J"},{"key":"2026021721495642700_ejhf70082-bib-0050","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s11695-025-07703-0","article-title":"Effectiveness of adjuvant semaglutide following bariatric metabolic surgery","volume":"35","author":"Ferguson","year":"2025","journal-title":"Obes Surg"},{"key":"2026021721495642700_ejhf70082-bib-0051","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.soard.2024.08.037","article-title":"A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass","volume":"21","author":"Lofton","year":"2025","journal-title":"Surg Obes Relat Dis"},{"key":"2026021721495642700_ejhf70082-bib-0052","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ehf2.14560","article-title":"Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists","volume":"11","author":"Cimino","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0053","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: A systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026021721495642700_ejhf70082-bib-0054","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026021721495642700_ejhf70082-bib-0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026021721495642700_ejhf70082-bib-0056","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021721495642700_ejhf70082-bib-0057","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021721495642700_ejhf70082-bib-0058","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"2026021721495642700_ejhf70082-bib-0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.06.007","article-title":"Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: A real-world study","volume":"139","author":"Trenas","year":"2025","journal-title":"Eur J Intern Med"},{"key":"2026021721495642700_ejhf70082-bib-0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior heart failure hospitalization, clinical outcomes, and response to Sacubitril\/valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0061","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.jacc.2021.08.064","article-title":"In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction","volume":"78","author":"Rao","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0062","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/cvr\/cvq271","article-title":"GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons","volume":"89","author":"Griffioen","year":"2011","journal-title":"Cardiovasc Res"},{"key":"2026021721495642700_ejhf70082-bib-0063","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.amjcard.2015.12.031","article-title":"Relation of elevated heart rate in patients with heart failure with reduced ejection fraction to one-year outcomes and costs","volume":"117","author":"DeVore","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0064","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"2026021721495642700_ejhf70082-bib-0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154452","article-title":"Myocardial ketone body utilization in patients with heart failure: The impact of oral ketone ester","volume":"115","author":"Monzo","year":"2021","journal-title":"Metabolism"},{"key":"2026021721495642700_ejhf70082-bib-0066","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ejhf.3424","article-title":"Anthropometric measures and long-term mortality in non-ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradox","volume":"27","author":"Butt","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0067","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ehjcvp\/pvaa108","article-title":"Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing","volume":"8","author":"El Hadidi","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026021721495642700_ejhf70082-bib-0068","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011518","article-title":"Anti-obesity medications in patients with heart failure: Current evidence and practical guidance","volume":"17","author":"Harrington","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"2026021721495642700_ejhf70082-bib-0070","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: A multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Martinez","year":"2022","journal-title":"J Clin Med"},{"key":"2026021721495642700_ejhf70082-bib-0071","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2337\/dc25-0690","article-title":"Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: A randomized controlled open-label pilot study examining a 16-week flexible titration regimen versus label-recommended 8-week semaglutide titration regimen","volume":"48","author":"Eldor","year":"2025","journal-title":"Diabetes Care"},{"key":"2026021721495642700_ejhf70082-bib-0072","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"2026021721495642700_ejhf70082-bib-0073","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026021721495642700_ejhf70082-bib-0074","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur Heart J"},{"key":"2026021721495642700_ejhf70082-bib-0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ejhf.1673","article-title":"European Society of Cardiology\/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure","volume":"22","author":"Seferovic","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"2026021721495642700_ejhf70082-bib-0077","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: Adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"key":"2026021721495642700_ejhf70082-bib-0078","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jchf.2024.10.023","article-title":"Growth differentiation factor-15 is associated with congestion-related anorexia and weight loss in advanced heart failure","volume":"13","author":"Monzo","year":"2025","journal-title":"JACC Heart Fail."},{"key":"2026021721495642700_ejhf70082-bib-0079","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrcardio.2017.51","article-title":"Muscle wasting and cachexia in heart failure: Mechanisms and therapies","volume":"14","author":"Haehling","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0080","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2026021721495642700_ejhf70082-bib-0081","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of Glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2026021721495642700_ejhf70082-bib-0082","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/cpt.2430","article-title":"Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes","volume":"111","author":"Faillie","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2026021721495642700_ejhf70082-bib-0083","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/ALN.0000000000004776","article-title":"ASA consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists","volume":"140","author":"Ushakumari","year":"2024","journal-title":"Anesthesiology"},{"key":"2026021721495642700_ejhf70082-bib-0084","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bja.2025.04.001","article-title":"Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement","volume":"135","author":"Oprea","year":"2025","journal-title":"Br J Anaesth"},{"key":"2026021721495642700_ejhf70082-bib-0085","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/anae.16541","article-title":"Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: A multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association","volume":"80","author":"El-Boghdadly","year":"2025","journal-title":"Anaesthesia"},{"key":"2026021721495642700_ejhf70082-bib-0086","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026021721495642700_ejhf70082-bib-0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: A post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026021721495642700_ejhf70082-bib-0088","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjcvp\/pvaf014","article-title":"Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: A cohort study","volume":"11","author":"Chen","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026021721495642700_ejhf70082-bib-0089","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11897-025-00704-1","article-title":"Therapeutic potential of GLP-1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) in obese patients","volume":"22","author":"Patel","year":"2025","journal-title":"Curr Heart Fail Rep"},{"key":"2026021721495642700_ejhf70082-bib-0090","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ejhf.3558","article-title":"Tailoring medical therapy for heart failure with preserved ejection fraction","volume":"27","author":"Inciardi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0091","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0092","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41569-025-01166-7","article-title":"Cardiac intermediary metabolism in heart failure: Substrate use, signalling roles and therapeutic targets","volume":"22","author":"Mericskay","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0093","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/ehf2.15345","article-title":"Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review","volume":"12","author":"Bauersachs","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0094","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ejhf.3703","article-title":"The crosstalk between immune activation and metabolism in heart failure. A scientific statement of the Heart Failure Association of the ESC","volume":"27","author":"Fragasso","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0095","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/ejhf.3709","article-title":"How to facilitate seamless translation from basic concepts to new heart failure drugs. A scientific statement of the Heart Failure Association of the ESC","volume":"27","author":"Tocchetti","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0096","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","article-title":"GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors","volume":"12","author":"Patel","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0097","first-page":"5690","article-title":"Impact of sacubitril\/valsartan on implantable defibrillator eligibility in heart failure: A real-world experience","volume":"25","author":"Monzo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026021721495642700_ejhf70082-bib-0098","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2026021721495642700_ejhf70082-bib-0099","article-title":"Clinical characteristics and outcomes of patients with heart failure with preserved ejection fraction and with reduced ejection fraction according to the prognostic nutritional index: Findings from PARADIGM-HF and PARAGON-HF","volume":"7","author":"Solano","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026021721495642700_ejhf70082-bib-0100","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10741-025-10481-7","article-title":"Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum","volume":"30","author":"Shahid","year":"2025","journal-title":"Heart Fail Rev"},{"key":"2026021721495642700_ejhf70082-bib-0101","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamacardio.2025.1775","article-title":"Finerenone according to frailty in heart failure: A prespecified analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Butt","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0102","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/ejhf.3694","article-title":"Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial","volume":"27","author":"Cunningham","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021721495642700_ejhf70082-bib-0103","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026021721495642700_ejhf70082-bib-0104","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021721495642700_ejhf70082-bib-0105","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.jacc.2024.08.033","article-title":"Why have we not been able to demonstrate reduced mortality in patients with HFmrEF\/HFpEF?","volume":"84","author":"Kondo","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: A narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"EClinicalMedicine."},{"key":"2026021721495642700_ejhf70082-bib-0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.05.008","article-title":"2025 ACC scientific statement on the management of obesity in adults with heart failure: A report of the American College of Cardiology","author":"Kittleson","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026021721495642700_ejhf70082-bib-0108","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/ejhf.3707","article-title":"Global heart failure epidemiology versus enrolment in pivotal trials: A formidable mismatch","volume":"27","author":"Baudry","year":"2025","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2465\/66833793\/eurjhf_27_11_2465.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2465\/66833793\/eurjhf_27_11_2465.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:50:19Z","timestamp":1771383019000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/11\/2465\/8470307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":108,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,27]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.70082","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"2025-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}